Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target

Rigel Pharmaceuticals is increasingly compelling because its outlook is supported by a multi-product commercial base, including Tavalisse, Rezlidhia, Gavreto, and the newly added Veppanu, which broadens near-term revenue drivers and reduces dependence on any single asset. The company’s commercial portfolio is modeled with continued growth from Tavalisse and Rezlidhia, stable contribution from Gavreto, and conservative but meaningful Veppanu uptake, while Kissei’s Japan filing for Rezlidhia creates additional milestone and royalty-like upside from a $10M upfront deal. Clinical and real-world data also strengthen the case: pralsetinib showed median PFS of 18.7 months versus 9.0 months in AcceleRET-Lung, and olutasidenib produced durable responses with estimated 48-month OS of 74% and EFS of 69% in long-term responders.

Rigel Pharmaceuticals is viewed negatively because the 10-for-1 reverse split on June 27, 2024 underscores ongoing capital structure stress rather than durable operating strength, while quarterly EPS may be distorted by a higher share count and rounding. Although REZLIDHIA showed encouraging real-world activity after venetoclax failure, the evidence base is still small—just 24 treated patients, a median treatment duration of 4.0 months, and median overall survival of 11.6 months—so it does not yet offset broader fundamental risks. The company remains reliant on a limited portfolio and partnered economics, with AstraZeneca taking overall responsibility for its lead oral RA asset, which leaves Rigel dependent on royalties and milestones rather than fully controlled, diversified revenue streams.